# US 2026/0242798 A1 · RNAi FORMULATION FOR INHIBITING PCSK9 GENE EXPRESSION AND USE THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0242798 A1
- Document ID: US20260242798A1
- Status: Published application
- Kind: A1
- Application number: 19/461,345
- Filed: 2026-01-27
- Published: 2026-08-20
- Earliest claimed: 2024-07-06
- Assignees: Mabwell (Shanghai) Bioscience Co., Ltd.
- Applicants: Mabwell (Shanghai) Bioscience Co., Ltd.
- Inventors: Fuzheng Yang; Hao Chen; Bing Jin; Denghui Hu; Chengxin Ma; Xun Gui
- Web page: https://patentgrep.com/patent/US20260242798A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/7125: Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/06: Antihyperlipidemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C12Y 304/21: Serine endopeptidases (3.4.21)
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/316: Phosphonothioates
- C12N 2310/343: having patterns, e.g. ==--==--==--
- C12N 2310/351: Conjugate
- C12N 2310/3519: Fusion with another nucleic acid
- C12N 2310/51: in polymeric form, e.g. multimers, concatemers
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12Y 304/21061: Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The present application provides an RNA inhibitor for inhibiting PCSK9 gene expression, which comprises an antisense strand, wherein the antisense strand comprises a complementary region that is complementary to at least a part of an mRNA encoding PCSK9, and the complementary region is 17-23 nucleotides in length. The antisense strand comprises the following nucleotide sequence: any one of SEQ ID NOs: 328-654, 1045-1107, 1125-1146, or 1149-1170, or a sequence differing by no more than 3 nucleotides therefrom. In addition, the present application also provides a pharmaceutical composition, which comprises the RNA inhibitor for inhibiting PCSK9 gene expression, and further comprises a delivery vehicle, and/or a physiologically acceptable excipient and/or carrier and/or diluent.

## Claims

### Claim at position 1

1-65. (canceled)

### Claim 66

An siRNA molecule that targets PCSK9, wherein the siRNA molecule comprises a sense strand comprising the nucleobase sequence of SEQ ID NO: 104 and an antisense strand comprising the nucleobase sequence of SEQ ID NO: 431.

### Claim 67 (depends on 66)

The siRNA of claim 66, wherein the sense strand comprises the nucleic acid sequence of SEQ ID NO: 991.

### Claim 68 (depends on 66)

The siRNA of claim 66, wherein the antisense strand comprises the nucleic acid sequence of SEQ ID NO: 1054.

### Claim 69 (depends on 66)

The siRNA of claim 66, wherein the sense strand comprises the nucleic acid sequence of SEQ ID NO: 991 and the antisense strand comprises the nucleic acid sequence of SEQ ID NO: 1054.

### Claim 70

A composition comprising a first siRNA molecule and a second siRNA molecule, wherein the first siRNA molecule targets PCSK9 and comprises a sense strand comprising the nucleobase sequence of SEQ ID NO: 104 and an antisense strand comprising the nucleobase sequence of SEQ ID NO: 431.

### Claim 71 (depends on 70)

The composition of claim 70, wherein the sense strand comprises the nucleic acid sequence of SEQ ID NO: 991 and the antisense strand comprises the nucleic acid sequence of SEQ ID NO: 1054.

### Claim 72 (depends on 70)

The composition of claim 70, wherein the second siRNA molecule targets Lp(a).

### Claim 73 (depends on 72)

The composition of claim 72, wherein the second siRNA molecule comprises a sense strand comprising the nucleobase sequence of SEQ ID NO: 1171 and an antisense strand comprising the nucleobase sequence of SEQ ID NO: 1172.

### Claim 74 (depends on 72)

The composition of claim 72, wherein the second siRNA molecule comprises a sense strand comprising the nucleic acid sequence of SEQ ID NO: 1173 and an antisense strand comprising the nucleic acid sequence of SEQ ID NO: 1174.

### Claim 75 (depends on 73)

The composition of claim 73 wherein the sense strand of the first siRNA molecule and the sense strand of the second siRNA molecule are linked.

### Claim 76 (depends on 75)

The composition of claim 75, wherein the sense strand of the first siRNA molecule and the sense strand of the second siRNA molecule are linked by a polynucleotide linker.

### Claim 77 (depends on 76)

The composition of claim 76, wherein the polynucleotide linker comprises a plurality of deoxyadenosines (dA) or a plurality of deoxythymidines (dT).

### Claim 78 (depends on 76)

The composition of claim 76, wherein the polynucleotide linker is sdAdAdAs, sdAdAdAdAs, sdAdAdAdAdAs, sdAdAdAdAdAdAs, sdTdTdTs, sdTdTdTdTs,
sdTdTdTdTdTs, or sdTdTdTdTdTdTs, wherein s is a phosphorothioate group.

### Claim 79 (depends on 76)

The composition of claim 76, wherein the sense strand of the first siRNA molecule linked to the sense strand of the second siRNA molecule comprises the nucleic acid sequence of SEQ ID NO: 1180.

### Claim 80 (depends on 70)

The composition of claim 70, further comprising a ligand targeting group conjugated to the sense strand.

### Claim 81 (depends on 80)

The composition of claim 80, wherein the ligand targeting group is conjugated to the 5′ or the 3′ of the sense strand.

### Claim 82 (depends on 80)

The composition of claim 80, wherein the ligand targeting group is an N-acetylgalactosamine.

### Claim 83 (depends on 82)

The composition of claim 82, wherein the N-acetylgalactosamine is L96 having the formula of:

### Claim 84

A composition comprising:
a first nucleic acid sequence comprising a sense strand comprising the nucleic acid sequence of SEQ ID NO: 1180 and a ligand targeting group conjugated to the 5′ and the 3′ of the sense strand;
a second nucleic acid sequence comprising an antisense strand comprising the nucleic sequence of SEQ ID NO: 1054; and
a third nucleic acid sequence comprising an antisense strand comprising the nucleic acid sequence of SEQ ID NO: 1174,
wherein the ligand targeting group is L96 having the formula of:

### Claim 85 (depends on 66)

A pharmaceutical composition comprising the siRNA molecule of claim 66.

### Claim 86 (depends on 70)

A pharmaceutical composition comprising the composition of claim 70.

### Claim 87 (depends on 72)

A pharmaceutical composition comprising the composition of claim 72.

### Claim 88 (depends on 84)

A pharmaceutical composition comprising the composition of claim 84.

### Claim 89 (depends on 85)

A method of inhibiting the expression of PCSK9 in a subject in need thereof, the method comprising administering the pharmaceutical composition of claim 85 to the subject.

### Claim 90 (depends on 86)

A method of inhibiting the expression of PCSK9 in a subject in need thereof, the method comprising administering the pharmaceutical composition of claim 86 to the subject.

### Claim 91 (depends on 87)

A method of inhibiting the expression of PCSK9 and Lp(a) in a subject in need thereof, the method comprising administering the pharmaceutical composition of claim 87 to the subject.

### Claim 92 (depends on 88)

A method of inhibiting the expression of PCSK9 and Lp(a) in a subject in need thereof, the method comprising administering the pharmaceutical composition of claim 88 to the subject.

### Claim 93 (depends on 88)

A method of treating hypercholesterolemia in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of claim 88.
